top of page
Untitled (40 × 20 in).png

Changing life sciences, one droplet at a time.

We are harnessing the hidden power of sound to revolutionize drug delivery.

Untitled design (6).png
What we do

WHAT WE DO

Drug delivery, simplified.

We are improving the care of millions of patients by formulating new and existing biologic products, traditionally administered through lengthy hospital-based intravenous injections,

into ultra highly concentrated subcutaneous

injections that are as simple as a flu shot.

Untitled design (3).png

Our platform brings

life-saving drug delivery

from the hospital to your home.

Syringe.png

Why subcutaneous delivery?

Untitled design (5).png

Why aren't more products like this?

As monoclonal antibodies (mAbs) approach the high concentrations necessary for small-volume subcutaneous delivery, they become increasingly viscous and unstable, making them extremely difficult to process, manufacture, and inject. Consequently, fewer than 50% of mAbs are available in subcutaneous form - limited to those requiring small doses or large injection volumes. This problem becomes even more challenging for new biotherapeutics, including antibody-drug conjugates (ADCs), bispecifics, and fusion proteins.

Every day, thousands of patients make the arduous journey to hospitals or infusion centers for their life saving therapies. Once there, they face a long and uncomfortable intravenous (IV) treatment, which burdens hospital resources, healthcare professionals, and the patients themselves. At AcousticaBio, we believe there's a better way to deliver these life-saving therapies - through subcutaneous administration. It's no surprise that the overwhelming majority of patients prefer subcutaneous injections over IV treatments - and for good reason! These formulations unlock significant benefits for patients, drug manufacturers, and the healthcare system as a whole.

Technology

We create ultra-high concentrations of biologics, exceeding 400 mg/mL.

Our microparticle suspension formulations are designed to achieve the optimal concentrations and characteristics necessary for effective subcutaneous delivery. 

OUR TECHNOLOGY

Our process is characterized by its gentle handling and versatility, accommodating a broad spectrum of materials with minimal product loss.

-Daniele Foresti, Founder

  • Where does AcousticaBio come in?
    We spent over 10 years discovering the hidden power of sound waves to process fluids at the microscale. Utilizing our patented acoustic-based platform and proprietary microparticle technology, we partner with biopharmaceutical companies to advance their biologic formulations beyond current technological limitations. Starting with our partners' new and existing biologics formulations, we create, develop, and manufacture ultra-high concentration, small-volume, low viscosity products, all without the use of solvents or cumbersome post-processing. These ultra-high concentration antibody formulations (HCAFs) uniquely achieve the safety, functionality, stability, and injectability required for subcutaneous administration.
  • How does AcousticaBio's platform work?
    We utilize a patented acoustophoretic technology platform, which combines "acoustic" (relating to sound) and "phoretic" (meaning movement or transport). Hence, our platform uses sound waves to generate microparticles directly in air! These microparticles encapsulate highly concentrated and viscous formulations with exceptional uniformity and control. The consistent size and shape of our microparticles, combined with their ability to flow in a controlled manner, allow them to easily move through narrow openings such as subcutaneous needles. This approach minimizes impact, resulting in virtually zero waste and minimal material loss. Importantly, our platform is largely carrier-independent, enabling us to process the widest range of materials of any available technology. We can handle material viscosities spanning more than four orders of magnitude!
Untitled (50 × 20 in).png

OUR SOLUTION DELIVERS

Easier injections
Painless subcutaneous injections allow for self-administration.

Safer access
Better drug delivery means less severe immune responses.

Reduced cost
Increased savings for patients, providers, and pharmaceutical companies alike.

Low viscosity
Particle suspensions allow us to overcome the viscosity
limitation.

Less aggregation
mAbs are stabilized within a polymer matrix resulting in less antibody aggregation.

Greater stability
Higher payload concentrations are encapsulated.

Careers

CAREERS

We're building a team of visionaries.
Come join us on our quest to revolutionize life sciences.
Interested in joining?

Follow us for updates

  • LinkedIn
bottom of page